Track Record

 

Our track record shows successful product development and regulatory approval. Our commercial experience ensures our clients' continued confidence in our distribution of their approved products.

 

 

•  Drug Delivery Systems: Fast Melt, Modified Release.

•  FDA INSPECTION: Please call for our EIR

•  The Company has just made a research and distribution agreement with a major U.S. pharmaceutical company for the mass introduction of its drug candidates.

Drug Application

ANDA/IND
Holder

Active Ingredient or Indication

Form

Strength

74-677

STASON

CAPTOPRIL
1997

Tablet

12.5, 25, 50, 100mg

74-912

STASON

SELEGILINE HYDROCHLORIDE
1998

Tablet

5mg

75-090

STASON

ACYCLOVIR
1999

Capsule

200mg

40-461

CLIENT

MERCAPTOPURINE
Approved Feb. 11, 2004

Tablet

50mg

40-644

STASON

CYPROHEPTADINE HYDROCHLORIDE
2006

Tablet

4mg

9 ANDAs

Marketing Partner

Cancer, BHP & Diabetic Treatments

Various

 

10 ANDAs

Standard Chem

Treating chronic conditions

Various

 

IND

Joint Venture

Oncology
Fast Track Status Granted
April 19, 2005

Topical

 

12 ANDAs

Marketing Partners

Various

Solids

 

4 ANDAs

STASON

Oncology

Inject.

 

 

 

 

 

 

Stason Partners & Affiliates